



## *Disclosure of total number of voting rights and number of shares in the capital at November 28, 2008*

Paris, December 5<sup>th</sup>, 2008 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

| Date              | Total number of outstanding shares | Total number of voting rights   |
|-------------------|------------------------------------|---|
| November 28, 2008 | 12, 896,834                        | Theoretical number of voting rights: 12, 896,834<br>(including own shares)<br><br>Number of real voting rights: 12, 837,089<br>(without own shares) |

### **About BioAlliance Pharma**

BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues.

### ***BioAlliance Pharma SA***

Dominique Costantini, President and CEO  
 Tel.: +33 1 45 58 76 01  
 dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO  
 Tel.: +33 1 45 58 71 00  
 nicolas.fellmann@bioalliancepharma.com

### ***ALIZE RP***

Caroline Carmagnol  
 Tel.: +33 6 64 18 99 59  
 caroline@alizerp.com